Virtual Library

Start Your Search

Gilbert Ferretti



Author of

  • +

    P2.18 - Treatment of Locoregional Disease - NSCLC (ID 191)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment of Locoregional Disease - NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.18-10 - Importance of the Multidisciplinary Tumor Board in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC) (Now Available) (ID 1107)

      10:15 - 18:15  |  Author(s): Gilbert Ferretti

      • Abstract
      • Slides

      Background

      Stage III Non-Small Cell Lung Cancer (NSCLC) represents a heterogeneous population with different treatment strategies, often in combination. The PACIFIC trial is changing practices. It is therefore necessary to evaluate our current practices in order to identify the patients that should most likely receive this treatment after chemoradiotherapy

      Method

      A database constructed from our weekly multidisciplinary thoracic oncology meetings was retrospectively screened from 01/2010 to 01/2017. Consecutive patients with stages III NSCLC were included. We aimed to describe proposed treatment strategies and those really performed

      Result

      Of the 411 patients studied, 249 had a stage IIIA NSCLC and 162 a stage IIIB NSCLC. Median age was 65 years [IQR 25%-75%, 58-72], 309 (75%) patients were male. The majority of the patients (n=270, 69%, 20 missing data) had an ECOG-Performance status of 0 or 1. Regarding histology, 199 (48%) patients had an adenocarcinoma and 199 (48%) a squamous cell carcinoma. Treatment strategies are described in Table 1. Sixty-nine (17%) patients received exclusive chemoradiotherapy, and 60 (15%) were planned for neoadjuvant chemotherapy for subsequent surgery. Among these 60 patients, after the first cycles of the initial chemotherapy, only 37 (62%) received surgery in accordance with the multidisciplinary meeting decision; 6 (10%) received concurrent chemoradiotherapy and 6 (10%) sequential chemoradiotherapy.

      figure1.jpg

      Conclusion

      In our cohort, 8% (32/411) of the stage III patients benefited from a chemoradiotherapy upfront. According to the PACIFIC study, these patients could receive adjuvant immunotherapy. We could ask if the patients planned for surgery after neoadjuvant chemotherapy should not be initially proposed for a concurrent chemoradiotherapy to give them the opportunity to receive adjuvant immunotherapy. Survival analyses according to treatment strategy are ongoing

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.